BioVie Analyst Ratings
BioVie Analyst Ratings
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a reiterated with a price target of $0.00 to $11.00. The current price BioVie (BIVI) is trading at is $5.06, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/18/2023 | 117.39% | Cantor Fitzgerald | → $11 | Reiterates | Overweight → Overweight |
| 05/17/2023 | 117.39% | Cantor Fitzgerald | → $11 | Reiterates | Overweight → Overweight |
| 05/17/2023 | 137.15% | Oppenheimer | → $12 | Reiterates | Outperform → Outperform |
| 02/14/2023 | 137.15% | Oppenheimer | → $12 | Reiterates | → Outperform |
| 09/28/2022 | 58.1% | EF Hutton | $14 → $8 | Maintains | Buy |
| 07/22/2022 | 38.34% | Cantor Fitzgerald | → $7 | Initiates Coverage On | → Overweight |
| 03/17/2022 | 176.68% | EF Hutton | $9 → $14 | Maintains | Buy |
| 03/15/2022 | 77.87% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
| 11/30/2021 | 433.6% | B. Riley Securities | $50 → $27 | Maintains | Buy |
| 01/15/2021 | 828.85% | B. Riley Securities | → $47 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/18/2023 | 117.39% | 坎托·菲茨杰拉德 | → 11 美元 | 重申 | 超重 → 超重 |
| 05/17/2023 | 117.39% | 坎托·菲茨杰拉德 | → 11 美元 | 重申 | 超重 → 超重 |
| 05/17/2023 | 137.15% | 奥本海默 | → 12 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 02/14/2023 | 137.15% | 奥本海默 | → 12 美元 | 重申 | → 跑赢大盘 |
| 2022 年 9 月 28 日 | 58.1% | EF Hutton | 14 美元 → 8 美元 | 维护 | 购买 |
| 07/22/2022 | 38.34% | 坎托·菲茨杰拉德 | → 7 美元 | 启动覆盖开启 | → 超重 |
| 03/17/2022 | 176.68% | EF Hutton | 9 美元 → 14 美元 | 维护 | 购买 |
| 2022 年 3 月 15 日 | 77.87% | 奥本海默 | → 9 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 11/30/2021 | 433.6% | B. 莱利证券 | 50 美元 → 27 美元 | 维护 | 购买 |
| 2021 年 1 月 15 日 | 828.85% | B. 莱利证券 | → 47 美元 | 启动覆盖开启 | → 购买 |
What is the target price for BioVie (BIVI)?
BioVie (BIVI) 的目标价格是多少？
The latest price target for BioVie (NASDAQ: BIVI) was reported by Cantor Fitzgerald on July 18, 2023. The analyst firm set a price target for $11.00 expecting BIVI to rise to within 12 months (a possible 117.39% upside). 6 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年7月18日公布了BioVie（纳斯达克股票代码：BIVI）的最新目标股价。这家分析公司将目标股价定为11.00美元，预计BIVI将在12个月内升至117.39％（可能上涨117.39％）。去年有6家分析公司公布了评级。
What is the most recent analyst rating for BioVie (BIVI)?
分析师对BioVie (BIVI) 的最新评级是多少？
The latest analyst rating for BioVie (NASDAQ: BIVI) was provided by Cantor Fitzgerald, and BioVie reiterated their overweight rating.
BioVie（纳斯达克股票代码：BIVI）的最新分析师评级由坎托·菲茨杰拉德提供，BioVie重申了他们的增持评级。
When is the next analyst rating going to be posted or updated for BioVie (BIVI)?
BioVie (BIVI) 的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioVie was filed on July 18, 2023 so you should expect the next rating to be made available sometime around July 18, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与BioVie的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。BioVie的最后一次评级是在2023年7月18日提交的，因此您应该预计下一个评级将在2024年7月18日左右公布。
Is the Analyst Rating BioVie (BIVI) correct?
分析师对 BioVie (BIVI) 的评级是否正确？
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a reiterated with a price target of $0.00 to $11.00. The current price BioVie (BIVI) is trading at is $5.06, which is within the analyst's predicted range.
虽然评级是主观的，会发生变化，但最新的BioVie（BIVI）评级得到了重申，目标股价为0.00美元至11.00美元。BioVie（BIVI）目前的交易价格为5.06美元，在分析师的预测区间内。
